Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat pharmacokinetics and safety study in young children with Duchenne muscular dystrophy
2024-511823-32-00Phase 2Authorised
- Sponsor
- Italfarmaco
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of givinostat in Duchenne muscular dystrophy (DMD) (2 cohorts), sponsored by Italfarmaco. Planned start Nov 2024; status: authorised.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-511823-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511823-32-00.